Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?

Bone-targeted agents should be considered for all postmenopausal women with high-risk, early-stage breast cancer. Targeting the microenvironment and normal host cells is a viable strategy for preventing cancer recurrences. See also pages 000-000.

http://ift.tt/2qoRrUE